Considerable improvement was reported in behavior (61%), communication (47%), and anxiety (39%), after at least 3 months of cannabis treatment

33% of children reduced their other medication doses and 24% stopped taking medications altogether

81.1% of patients reported overall treatment success – defined as experiencing at least moderate improvement in their condition without serious adverse effects

73.4% of patients reported improved sleep; 13.2% reported their sleep problems were fully relieved

80.8% of patients reported improved depression‐related symptoms

61.9% of patients reported their quality of life (QOL) to be “good or very good,” whereas only 2.7% of patients rated their QOL at this level prior to beginning treatment; QOL components include appetite, sleep quality, and sexual activity

Overall pain intensity reduced from a median of 9.0 at baseline to 5.0 after six months

22.2% of patients stopped or reduced their dosage of opioids; 20.3% reduced their dosage of benzodiazepines

90.2% of patients reported an improvement in symptoms after six months treatment

Symptoms improved included depression (100%), restlessness (89.8%), rage attacks (89%), anxiety (88.8%), seizures (84.6%), agitation (83.8%), tics (80%), digestion problems (62.5%), constipation (62.5%), sleep problems (58.6%), and more

Good quality of life was indicated by 31.1% of patients at intake; at six months, QOL increased to 66.8%

Patients reported improvement in sleep, positive mood, and ability to dress and shower independently

34.3% of patients decreased medication consumption, including antipsychotics, antiepileptics, antidepressants, hypnotics, and sedatives

20% of patients stopped taking antipsychotics

Cannabis appears to be a well-tolerated, safe and effective option to relieve ASD symptoms

The mean ranking of efficacy was 3.85 out of 5, indicating a positive response to medical cannabis

Patients reported reduction in tic severity, better sleep, and improved mood

CBD and Avidekel extracts are as efficient as Copaxone in alleviating the symptoms of EAE (animal model of brain inflammation) in lab mice.

Avidekel may be useful in the treatment of MS symptoms.

CBD-enriched 5% cannabis oil with CBD:THC ratios of 6:1 and 20:1 are effective in reducing the severity of dystonia and spasticity, and improving motor function ability and quality of life

All patients demonstrated mood and appetite improvement

Patients treated with the 6:1 ratio oil demonstrated sleep improvement

Patients treated with the 20:1 ratio oil demonstrated improvement in constipation

95.9% of patients reported an improvement in their condition

Prior to treatment, 52.9% of patients reported their pain in the 8-10 interval; after six months, only 4.6% of patients reported this intensity

Prior to treatment, only 18.7% of patients reported good quality of life; after six months, 69.5% of patients reported good quality of life

The most improved symptoms were nausea and vomiting (91%), sleep disorders (87.5%), restlessness (87.5%), anxiety and depression (84.2%), pruritus (82.1%) and headaches (81.4%)

35.1% of patients decreased their drug consumption, including analgesics, sedatives, corticosteroids, and opioids

36% of patients stopped taking opioids

Reported pain significantly reduced from a median of 8/10 to 4/10

Prior to treatment, 66.8% of patients reported high pain-intensity; at six months, this number decreased to only 7.6% of patients

93.7% of patients reported that the cannabis treatment improved their condition

35.1% of patients reported a decrease in the number of drugs taken or the dosage

18.1% of patients stopped using opioid analgesics or reduced their dose

The most common reported side effects were dizziness (9.7%) and dry mouth (7.1%)

82.2% of patients reported that cannabis improved their overall symptoms

81.4% of patients reported that their pain was reduced

76.1% of patients reported an improvement in mood

73.2% of patients reported tremor reduction

72.7% of patients reported reduced muscle stiffness

71.1% of patients reported an improvement in sleep quality

The full-plant extract of Avidekel, which is high in CBD and low in THC, provided a correlative anti-inflammatory and anti-pain dose-response (i.e. as the dose was increased, the pain and inflammation decreased in correlation), superior to the bell-shaped dose-response of isolated CBD, which exhibited less consistent anti-inflammatory and anti-pain properties at lower and higher doses

Avidekel extract exhibited superior anti-inflammatory effectiveness compared to tramadol (an opioid analgesic) and aspirin (a non-steroid anti-inflammatory)

Complete remission (CDAI score <150) was achieved by 5 of the 11 patients in the cannabis group

Clinical response (decrease in CDAI score of >100) was observed in 10 of the 11 patients

3 of the 11 patients were weaned from steroid dependency

The cannabis group reported significantly less pain, and improved appetite and quality of life

21 of the 30 patients improved significantly with cannabis treatment

The average Harvey Bradshaw Index improved from 14 +/- 6.7 to 7 +/- 4.7 (P<.001); the index measures general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and related complications

The mean number of bowel movements decreased from 8 to 5 per day

The need for other medication was significantly reduced; most notably, the number of patients needing steroid treatment reduced from 26 to 4